Related Experiment Video
Updated: May 27, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Using molecular markers to help predict who will fail after radical prostatectomy.
Gregory P Swanson1, David Quinn
1Departments of Radiation Oncology, Radiology, and Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive MC 7889, San Antonio, TX 78229, USA.
Prostate Cancer
|November 19, 2011
Summary
Adjuvant therapy improves outcomes for prostate cancer patients post-prostatectomy. This review assesses molecular markers for predicting recurrence risk, aiming to personalize treatment and avoid unnecessary interventions.
Area of Science:
- Oncology
- Urology
- Molecular Diagnostics
Background:
- Adjuvant therapy improves survival and reduces recurrence after prostatectomy for prostate cancer.
- Current prognostic markers (PSA, Gleason score, pathological stage) lack specificity.
- Accurate prediction of treatment failure is needed to personalize adjuvant therapy decisions.
Purpose of the Study:
- To comprehensively review the literature on molecular markers for predicting outcomes after radical prostatectomy.
- To evaluate the utility of various molecular markers and gene signatures in prognostic stratification.
- To determine the current status and clinical relevance of molecular markers in prostate cancer management.
Main Methods:
- Systematic literature review of phase III trials and prognostic studies.
- Analysis of data on molecular markers and gene signatures in predicting prostate cancer recurrence and survival.
- Assessment of the specificity and utility of identified markers.
Main Results:
- Standard markers (PSA, Gleason, stage) have limitations in predicting treatment failure.
- Numerous molecular markers and gene signatures have been investigated.
- The clinical utility and widespread applicability of many novel markers remain unclear.
Conclusions:
- There is a significant unmet need for more specific prognostic markers in prostate cancer.
- Further research is required to validate novel molecular markers and gene signatures for clinical use.
- Accurate prognostic tools are essential for optimizing adjuvant therapy strategies and patient outcomes.
